- Home
- ALLT vs YMAB Comparison
ALLT vs YMAB Comparison
Compare ALLT & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLT
- YMAB
- Stock Information
- Founded
- ALLT 1996
- YMAB 2015
- Country
- ALLT Israel
- YMAB United States
- Employees
- ALLT N/A
- YMAB N/A
- Industry
- ALLT Telecommunications Equipment
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ALLT Telecommunications
- YMAB Health Care
- Exchange
- ALLT Nasdaq
- YMAB Nasdaq
- Market Cap
- ALLT 229.8M
- YMAB 270.5M
- IPO Year
- ALLT 2006
- YMAB 2018
- Fundamental
- Price
- ALLT $5.53
- YMAB $4.50
- Analyst Decision
- ALLT Buy
- YMAB Buy
- Analyst Count
- ALLT 1
- YMAB 11
- Target Price
- ALLT $13.00
- YMAB $18.73
- AVG Volume (30 Days)
- ALLT 565.5K
- YMAB 322.9K
- Earning Date
- ALLT 05-28-2025
- YMAB 03-04-2025
- Dividend Yield
- ALLT N/A
- YMAB N/A
- EPS Growth
- ALLT N/A
- YMAB N/A
- EPS
- ALLT N/A
- YMAB N/A
- Revenue
- ALLT $92,195,000.00
- YMAB $87,685,000.00
- Revenue This Year
- ALLT $6.43
- YMAB $20.07
- Revenue Next Year
- ALLT $5.83
- YMAB $8.76
- P/E Ratio
- ALLT N/A
- YMAB N/A
- Revenue Growth
- ALLT N/A
- YMAB 3.38
- 52 Week Low
- ALLT $1.99
- YMAB $4.25
- 52 Week High
- ALLT $9.44
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- ALLT 40.14
- YMAB 36.51
- Support Level
- ALLT $5.45
- YMAB $4.65
- Resistance Level
- ALLT $7.00
- YMAB $5.25
- Average True Range (ATR)
- ALLT 0.42
- YMAB 0.30
- MACD
- ALLT 0.03
- YMAB 0.02
- Stochastic Oscillator
- ALLT 14.04
- YMAB 21.92
About ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. It has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.